TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years By Cancer History Project October 26, 2012
TCL Archive Two Phase II Trials Display Ramucirumab Potential Efficacy By Cancer History Project October 26, 2012
TCL Archive Gene Variant Associated With 44 Percent Cancer Risk Reduction By Cancer History Project October 26, 2012
TCL Archive Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant By Cancer History Project October 26, 2012
TCL Archive HCT Survivors More Likely To Show Heart Disease Risk Factors By Cancer History Project October 26, 2012
TCL Archive PV-10 Produces 51 Percent Response Rate in Phase II Trial By Cancer History Project October 26, 2012
TCL Archive Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk By Cancer History Project October 26, 2012
TCL Archive Three Studies Test Oncotype DX In Breast and Colon Cancers By Cancer History Project October 26, 2012
Article Robert Mayer talks about the half-century of misses that preceded the development of daraxonrasib By Cancer History Project
Primary Source Backwater to Blockbuster: St. Jude Children’s Research Hospital By Cancer History Project
